Featured Content

H. Jack West, MD
Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA; CEO, Global Resource for Advancing Cancer Education (GRACE)

Cuba's Lung Cancer Vaccine: Hype or Hope?

(Medscape Medical News) Aug 26, 2016 - With relations thawing between the US and Cuba, a lung cancer vaccine has caught the attention of the cancer community and the media.

Commentary: To cut to the chase, the answer is that it's HYPE. It seems to provide a very modest survival benefit, but it is...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

CTI BioPharma Announces Top-Line Results From PERSIST-2 Phase 3 Trial Of Pacritinib For High-Risk Patients With Advanced Myelofibrosis

(Yahoo! Finance) Aug 29, 2016 - CTI BioPharma Corp. today announced top-line results from PERSIST-2, a randomized, controlled Phase 3 clinical trial comparing pacritinib, an investigational oral multikinase inhibitor, with physician-specified best available therapy (BAT), including ruxolitinib, for the treatment of patients with myelofibrosis whose platelet counts are less than 100,000 per microliter -- a patient population with high-risk advanced disease.
read article »

To Help Patients, Lawmakers Pushed Access To A Controversial Doctor, Documents Show

(STAT/Special Report) Aug 29, 2016 - The call to Congressman Ted Yoho’s office was a matter of life and death: A constituent was seeking help for a 5-year-old great-nephew who was suffering from a terrible brain tumor.
read article »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Cuba's Lung Cancer Vaccine: Hype or Hope? (Medscape Medical News)

To cut to the chase, the answer is that it's HYPE. It seems to provide a very modest survival benefit, but it is...posted by: H. Jack West, MD

Study Finds Links Between Physicians Setting Cancer Care Guidelines And Drug Industry (UNC Lineberger)

I would venture to say that the link between payments and the outcomes of the guideline recommendations is as weak...posted by: Winston Wong, PharmD

Mylan to Lower EpiPen Cost for Some Patients (New York Times)

This is a good example of just how complex pricing and reimbursement is in the US healthcare system. Mylan is...posted by: Winston Wong, PharmD

ACOs Save Medicare $466M Last Year But Quality Improvements Are Mixed (KHN Morning Briefing)

So we see the number on the savings, with little correlation on the quality improvement. What this tells me is...posted by: Winston Wong, PharmD

Similar Immunotherapy Trials, Different Results: Early Signals From PD-1 Checkpoint Inhibitors in First-Line NSCLC (Medscape Oncology)

Patient selection biases and our attempts to compare dissimilar trials makes rapid assessment of these lung cancer...posted by: Dean Gesme, MD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board

Navigating Cancer has 1 job posted.


Bayer Pharmaceuticals has 1 job posted.


Touchpoint Solutions has over 20 jobs posted.


Check out the OBR Job Board here.





The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
CTIC +14.86%
THLD +12.22%
ARGS +7.41%
MNKD -5.58%
KERX -5.47%
MTP -5.00%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: September 1, 2016
Company: Blincyto® (blinatumomab)
Product: Amgen Inc.

Date: September 10, 2016
Company: Genmab A/S / Novartis
Product: Arzerra® (ofatumumab)

Date: Q3 2016
Company: OncoGenex Pharmaceuticals
Product: Custirsen

See All OBR Radar items»